Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

9 Meters Biopharma Inc. (INNT)

9 Meters Biopharma Inc. (INNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,142
  • Shares Outstanding, K 41,325
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,050 K
  • 60-Month Beta -0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/08/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4101 +36.55%
on 04/03/20
0.7600 -26.32%
on 04/29/20
+0.0900 (+19.15%)
since 04/01/20
3-Month
0.3701 +51.31%
on 03/18/20
0.8400 -33.33%
on 02/06/20
-0.1900 (-25.33%)
since 01/31/20
52-Week
0.3701 +51.31%
on 03/18/20
1.6700 -66.47%
on 05/16/19
-0.9800 (-63.64%)
since 05/01/19

Most Recent Stories

More News
9 Meters Biopharma, a Rare, Orphan and Unmet Needs GI-Focused Company, is Created with the Transformative Merger Between Innovate Biopharmaceuticals and RDD Pharma

Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC

INNT : 0.5600 (-20.23%)
BDSI : 4.79 (-0.62%)
Innovate Biopharmaceuticals Announces Full Year 2019 Financial Results And Strategic And Operational Updates

RALEIGH, NC / ACCESSWIRE / March 20, 2020 / (the "Company" or "Innovate") (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced...

INNT : 0.5600 (-20.23%)
Innovate Biopharmaceuticals Affirms Timeline for Closing of Merger with RDD Pharma Ltd. Closing Expected Around the End of the First Quarter of 2020

Israeli Regulatory Approvals Appear on Track for Late March 2020 to Allow Closing of the Merger

INNT : 0.5600 (-20.23%)
Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts for the 2020 Digestive Disease Week (DDW) Conference

Highlighting Larazotide's Effect across the Gut-Vascular Barrier - a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory Diseases

INNT : 0.5600 (-20.23%)
Innovate Biopharmaceuticals Announces Shareholder Approval of All Proposals in Connection with the Pending Merger with RDD Pharma Ltd. to Create 9 Meters Biopharma, a GI-focused Platform Company

INNT : 0.5600 (-20.23%)
RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline

RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent ("LOI") to acquire Naia Rare Diseases ("Naia"),...

INNT : 0.5600 (-20.23%)
Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

Deep Clinical-Stage Pipeline Combined With World-Class Leadership Team

INNT : 0.5600 (-20.23%)
BDSI : 4.79 (-0.62%)
Innovate Biopharmaceuticals, Inc. Announces First Patient Dosed in the First Phase 3 Clinical Trial for Patients with Celiac Disease

CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial

INNT : 0.5600 (-20.23%)
Innovate Biopharmaceuticals Reports Second Quarter 2019 Results and Corporate Updates

Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships

INNT : 0.5600 (-20.23%)
Innovate Biopharmaceuticals Announces Corporate Update and Expected Date for Second Quarter Earnings Release

Innovate undertakes succession planning for a chief executive officer

INNT : 0.5600 (-20.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade INNT with:

Business Summary

N/A

See More

Key Turning Points

2nd Resistance Point 0.7793
1st Resistance Point 0.6697
Last Price 0.5600
1st Support Level 0.5007
2nd Support Level 0.4413

See More

52-Week High 1.6700
Fibonacci 61.8% 1.1734
Fibonacci 50% 1.0200
Fibonacci 38.2% 0.8667
Last Price 0.5600
52-Week Low 0.3701

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar